Cargando…

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma

BACKGROUND: The prognostic significance of ALK rearrangement is still contradictory. Here, we aimed to investigate the clinical characteristics and outcomes of lung adenocarcinoma patients with ALK rearrangement, and analyze whether these patients benefited from targeted therapy. METHODS: This was a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Huan, Shan, Guangyao, Cai, Benjie, Bi, Guoshu, Chen, Zhencong, Liang, Jiaqi, Besskaya, Valeria, Zheng, Yuansheng, Guo, Weigang, Wang, Lin, Xu, Songtao, Zhan, Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590901/ https://www.ncbi.nlm.nih.gov/pubmed/34596344 http://dx.doi.org/10.1111/1759-7714.14170

Ejemplares similares

Hepatic nuclear factor 4 alpha promotes the ferroptosis of lung adenocarcinoma via transcriptional activation of cytochrome P450 oxidoreductase
por: Besskaya, Valeria, et al.
Publicado: (2023)

miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways
por: Bi, Guoshu, et al.
Publicado: (2022)

Genomic And Tumor Microenvironment Differences Between Cell Cycle Progression Pathway Altered/Non-Altered Patients With Lung Adenocarcinoma
por: Shan, Guangyao, et al.
Publicado: (2022)

Multi-Omics Analysis of Cancer Cell Lines with High/Low Ferroptosis Scores and Development of a Ferroptosis-Related Model for Multiple Cancer Types
por: Shan, Guangyao, et al.
Publicado: (2021)

Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma
por: Li, Pupu, et al.
Publicado: (2019)

Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation
por: Zeng, Dejun, et al.
Publicado: (2021)

A nomogram to predict prognosis of patients with lung adenosquamous carcinoma: a population-based study
por: Liang, Jiaqi, et al.
Publicado: (2020)

Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas
por: Jin, Xing, et al.
Publicado: (2021)

Enlarged Mediastinal Lymph Nodes in Computed Tomography are a Valuable Prognostic Factor in Non-Small Cell Lung Cancer Patients with Pathologically Negative Lymph Nodes
por: Zheng, Yuansheng, et al.
Publicado: (2020)

HNF4G increases cisplatin resistance in lung adenocarcinoma via the MAPK6/Akt pathway
por: Liang, Jiaqi, et al.
Publicado: (2023)

Landscape and dynamics of single tumor and immune cells in early and advanced‐stage lung adenocarcinoma
por: Chen, Zhencong, et al.
Publicado: (2021)

Signatures of malignant cells and novel therapeutic targets revealed by single‐cell sequencing in lung adenocarcinoma
por: Liang, Jiaqi, et al.
Publicado: (2022)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

Clinicopathological and Prognostic Significance of EML4-ALK Rearrangement in Patients with Surgically Resected Lung Adenocarcinoma: A Propensity Score Matching Study
por: Shi, Jinghan, et al.
Publicado: (2020)

Ligand-receptor interaction atlas within and between tumor cells and T cells in lung adenocarcinoma
por: Chen, Zhencong, et al.
Publicado: (2020)

Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement
por: Gao, Qiongqiong, et al.
Publicado: (2017)

Genetic and microenvironmental differences in non-smoking lung adenocarcinoma patients compared with smoking patients
por: Sui, Qihai, et al.
Publicado: (2020)

Identification of the relationship between single-cell N6-methyladenosine regulators and the infiltrating immune cells in esophageal carcinoma
por: Bian, Yunyi, et al.
Publicado: (2023)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

Analysis of the clinicopathological characteristics, genetic phenotypes, and prognostic of pure mucinous adenocarcinoma
por: Chen, Zhencong, et al.
Publicado: (2019)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
por: Kim, Hyungjin, et al.
Publicado: (2019)

Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types
por: Bi, Guoshu, et al.
Publicado: (2021)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Decreased Tertiary Lymphoid Structures in Lung Adenocarcinomas with ALK Rearrangements
por: Zou, Yi, et al.
Publicado: (2022)

Dissecting the single-cell transcriptome network in patients with esophageal squamous cell carcinoma receiving operative paclitaxel plus platinum chemotherapy
por: Chen, Zhencong, et al.
Publicado: (2021)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022)

Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin
por: Moatter, Samar, et al.
Publicado: (2018)

ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
por: Bi, Rui, et al.
Publicado: (2019)

KLF11 regulates lung adenocarcinoma ferroptosis and chemosensitivity by suppressing GPX4
por: Zhao, Guangyin, et al.
Publicado: (2023)

Thyroid metastasis from lung adenocarcinoma with EML4-ALK rearrangement
por: Kawamoto, Hironori, et al.
Publicado: (2016)

Clonally‐related primary ALK rearranged adenocarcinoma and associated metastatic lesions
por: Zhu, You‐cai, et al.
Publicado: (2018)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma
por: An, Rong, et al.
Publicado: (2016)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy
por: Incharoen, Pimpin, et al.
Publicado: (2016)

Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Marino, Federica Zito, et al.
Publicado: (2015)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

Identification and validation of the mitochondrial function related hub genes by unsupervised machine learning and multi-omics analyses in lung adenocarcinoma
por: Jin, Xing, et al.
Publicado: (2022)

The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives
por: Cognigni, Valeria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ometgnad1kok60i29q185gk85o